Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 85,369 |
|
|||||
| News | - | ||||||
| Day High | 5.185 | Low High |
|||||
| Day Low | 4.96 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aileron Therapeutics Inc | ALRN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 5.00 | 17:16:11 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 5.07 | 4.96 | 5.185 | 5.00 | 5.00 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 803 | 85,369 | $ 5.03 | $ 429,000 | - | 1.01 - 7.42 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 166 | $ 5.00 | USD |
Aileron Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 24.23M | 4.89M | - | 0 | -27.33M | -5.59 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Aileron Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALRN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.94 | 5.43 | 4.27 | 4.84 | 88,064 | 0.06 | 1.21% |
| 1 Month | 6.67 | 7.42 | 4.12 | 5.11 | 146,887 | -1.67 | -25.04% |
| 3 Months | 4.04 | 7.42 | 4.04 | 5.21 | 66,677 | 0.96 | 23.76% |
| 6 Months | 1.21 | 7.42 | 1.01 | 3.98 | 101,310 | 3.79 | 313.22% |
| 1 Year | 1.43 | 7.42 | 1.01 | 3.64 | 59,281 | 3.57 | 249.65% |
| 3 Years | 25.80 | 28.00 | 1.01 | 11.35 | 325,580 | -20.80 | -80.62% |
| 5 Years | 34.00 | 49.40 | 1.01 | 22.83 | 628,671 | -29.00 | -85.29% |
Aileron Therapeutics Description
| Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. |
